Abstract
Despite widespread interest, few serum biomarkers have been introduced to the clinic over the past 20 years. Each approach to ovarian cancer biomarker discovery has its own advantages and disadvantages and it seems likely that a global biomarker discovery platform that mines all possible sources for biomarkers might be more useful. Such data could be combined with information from relevant microarray data, bioinformatic analyses and literature searches. This proposed integrated systems biology approach has the potential to yield promising ovarian cancer markers for diagnosis, prognosis and monitoring of patients during therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
Konstantinopoulos, P. A., Spentzos, D. & Cannistra, S. A. Gene-expression profiling in epithelial ovarian cancer. Nature Clin. Pract. Oncol. 5, 577–587 (2008).
Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med. 351, 2519–2529 (2004).
Diamandis, E. P., Fritsche, H. A., Lilja, H., Chan, D. W. & Schwartz, M. K. Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. (AACC Press, Washington DC., 2002).
Kohn, E. C., Mills, G. B. & Liotta, L. Promising directions for the diagnosis and management of gynecological cancers. Int. J. Gynaecol. Obstet. 83 (Suppl. 1), 203–209 (2003).
Rustin, G. J., Nelstrop, A. E., Tuxen, M. K. & Lambert, H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7, 361–364 (1996).
Huhtinen, K., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100, 1315–1319 (2009).
Meinhold-Heerlein, I. et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin. Cancer Res. 13, 458–466 (2007).
Menon, U. et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327–340 (2009).
Visintin, I. et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065–1072 (2008).
Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054–1061 (2001).
Ransohoff, D. F. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst. 97, 315–319 (2005).
Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M. & Potter, J. D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 100, 1432–1438 (2008).
Jacobs, I. J. & Menon, U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics. 3, 355–366 (2004).
Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1, 845–867 (2002).
Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).
Karsan, A. et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525–1528 (2005).
Banks, R. E. et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51, 1637–1649 (2005).
Diamandis, E. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 96, 353–356 (2004).
Diamandis, E. P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell Proteomics 3, 367–378 (2004).
Simpkins, F., Czechowicz, J. A., Liotta, L. & Kohn, E. C. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics 6, 647–653 (2005).
Su, F. et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark. Insights 2, 369–375 (2007).
Nossov, V. et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 199, 215–223 (2008).
Zhang, Z. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882–5890 (2004).
Diamandis, E. P. Validation of breast cancer biomarkers identified by mass spectrometry. Clin. Chem. 52, 771–772 (2006).
Chang, H. W. et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Cancer Inst. 94, 1697–1703 (2002).
Stroun, M. et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46, 318–322 (1989).
Adam, R. A. & Adam, Y. G. Malignant ascites: past, present, and future. J. Am. Coll. Surg. 198, 999–1011 (2004).
Tamsma, J. T., Keizer, H. J. & Meinders, A. E. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann. Oncol. 12, 1353–1357 (2001).
Gortzak-Uzan, L. et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7, 339–351 (2008).
Kondo, T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB. Rep. 41, 626–634 (2008).
Good, D. M. et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res. 6, 4549–4555 (2007).
Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76–84 (2002).
Bengtsson, S. et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J. Proteome Res. 6, 1440–1450 (2007).
Kulasingam, V. & Diamandis, E. P. Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer 123, 2007–2012 (2008).
Faca, V. M. et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE 3, e2425 (2008).
Kelly-Spratt, K. S., Kasarda, A. E., Igra, M. & Kemp, C. J. A mouse model repository for cancer biomarker discovery. J. Proteome Res. 7, 3613–3618 (2008).
Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nature Rev. Cancer 7, 645–658 (2007).
Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966–971 (2007).
Pitteri, S. J. et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS ONE 4, e7916 (2009).
Bignotti, E. et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405–416 (2006).
Welsh, J. B. et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. USA 100, 3410–3415 (2003).
Tan, D. S., Lambros, M. B., Natrajan, R. & Reis-Filho, J. S. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab. Invest. 87, 737–754 (2007).
Spentzos, D. et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22, 4700–4710 (2004).
Moore, R. G. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112, 40–46 (2009).
Vargo-Gogola, T. & Rosen, J. M. Modelling breast cancer: one size does not fit all. Nature Rev. Cancer 7, 659–672 (2007).
Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnol. 24, 971–983 (2006).
Kuk, C. et al. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol. Cell Proteomics 8, 661–669 (2009).
Gunawardana, C. G. et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteome. Res. 8, 4705–4713 (2009).
Kuk, C. et al. Nidogen-2: a new serum biomarker for ovarian cancer. Clin. Biochem. 43, 355–361 (2009).
Hellstrom, I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695–3700 (2003).
Moore, R. G. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108, 402–408 (2008).
Davidson, B. et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 100, 2139–2147 (2004).
He, Z. & Bateman, A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J. Mol. Med. 81, 600–612 (2003).
Jones, M. B., Spooner, M. & Kohn, E. C. The granulin-epithelin precursor: a putative new growth factor for ovarian cancer. Gynecol. Oncol. 88, S136–S139 (2003).
Jones, M. B. et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res. 9, 44–51 (2003).
Simpson, R. J., Bernhard, O. K., Greening, D. W. & Moritz, R. L. Proteomics-driven cancer biomarker discovery: looking to the future. Curr. Opin. Chem. Biol. 12, 72–77 (2008).
Diamandis, E. P., Hanash, S., Lopez, M., Carr, S. & Petricoin, E. F. Protein quantification by mass spectrometry: is it ready for prime time? Clin. Chem. 55, 1427–1430 (2009).
Addona, T. A. et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nature Biotechnol. 27, 633–641 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Kulasingam, V., Pavlou, M. & Diamandis, E. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 10, 371–378 (2010). https://doi.org/10.1038/nrc2831
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2831
This article is cited by
-
Discovery of novel glioma serum biomarkers by proximity extension assay
Clinical Proteomics (2023)
-
A review of deep learning applications in human genomics using next-generation sequencing data
Human Genomics (2022)
-
Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses
Hereditas (2020)
-
Deblender: a semi−/unsupervised multi-operational computational method for complete deconvolution of expression data from heterogeneous samples
BMC Bioinformatics (2018)
-
Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway
Cell Death & Disease (2018)